Detailed Coverage

Solara Active Pharma Sciences Ltd. Q1 FY27 Results

Solara Active Pharma's overall revenue surged 20% year-on-year to ₹3,843 million in Q1 FY27. The company also reported its highest EBITDA and Profit After Tax (PAT) in the last eighteen quarters.

Reader Takeaway: Resilient base business drives growth; strategic decision on Ibuprofen business pending.

What just happened

Solara Active Pharma Sciences Ltd. announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27). The company achieved overall revenue of ₹3,843 million, a 20% increase year-on-year. EBITDA rose 10% YoY to ₹635 million, and PAT saw a significant jump of 55% to ₹163 million compared to the previous year. This marks the highest EBITDA and PAT reported in the last eighteen quarters.

Why this matters

The strong performance in the 'Base business' segment, which grew revenue by 24% YoY to ₹3,077 million, highlights the company's core operational strength. However, the Ibuprofen business continues to be a drag, posting a negative EBITDA of ₹87 million on revenues of ₹765 million. The company is actively exploring strategic alternatives for this segment.

The backstory

Solara Active Pharma has been working on strengthening its balance sheet and improving profitability. The company recently completed a rights issue and has been using operational cash flows to reduce its net debt. The Ibuprofen segment has been facing challenges due to commodity pricing and input cost pressures.

What changes now

The company is actively evaluating strategic options for its Ibuprofen business, with a decision expected by the end of Q2 FY27. This strategic review is a prerequisite for the planned carve-out of the polymers and CRAMS business, which is currently on hold.

Risks to watch

The primary concern remains the persistent losses from the Ibuprofen business, which impacts consolidated profitability. Additionally, geopolitical tensions in West Asia pose risks to raw material costs and supply chain stability, affecting margins across segments.

Peer comparison

While not explicitly detailed in the filing, Solara's performance in its base business indicates strong competitive positioning in its specialized segments. The challenges in the Ibuprofen segment are common in the commodity API market, where price volatility and input costs are critical factors.

Context metrics (time-bound)

• Overall Revenue (Q1 FY27): ₹3,843 million (up 20% YoY)
• Overall EBITDA (Q1 FY27): ₹635 million (up 10% YoY)
• Overall PAT (Q1 FY27): ₹163 million (up 55% YoY)
• Base Business Revenue (Q1 FY27): ₹3,077 million (up 24% YoY)
• Ibuprofen Business EBITDA (Q1 FY27): -₹87 million
• Net Debt (as of June 30, 2026): ₹4,795 million
• Net Debt to EBITDA Target: 1.7x by March 2027

What to track next

Investors should closely monitor the company's decision on the Ibuprofen business strategy, expected by the end of Q2 FY27. The progress on debt reduction and achieving the Net Debt to EBITDA target will also be key indicators.